Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor

Cancer Research

Volumn 58, Issue 20, 1998, Pages 4640-4645

  Hobisch, Alfred ^a   Eder, Iris E ^a   Putz, Thomas ^a   Horninger, Wolfgang ^a   Bartsch, Georg ^a   Klocker, Helmut ^a   Culig, Zoran ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; ESTROGEN RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; METRIBOLONE; MITOGEN ACTIVATED PROTEIN KINASE; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN SECRETION; REPORTER GENE; SIGNAL TRANSDUCTION;

DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTORS, ANDROGEN; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032532688     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Kishimoto, T., Akira, S., and Taga, T. Interleukin-6 and its receptor: a paradigm for cytokines. Science (Washington DC), 258: 593-597, 1992.
2. Seymour, J. F., Talpaz, M., Hagemeister, F. B., Cabanillas, F., and Kurzrock, R. Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgin's disease. Am. J. Med., 102: 21-28, 1997.
3. Oka, M., Yamamoto, K., Takahashi, M., Hakozaki, M., Abe, T., Iizuka, N., Hazama, S., Hirazawa, K., Hayashi, H., Tangoku, A., Hirose, K., Ishihara, T., and Suzuki, T. Relationship between serum levels of interleukin-6. various disease parameters, and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res., 56: 2776-2780, 1996.
4. Twillie, D. A., Eisenberger, M. A., Carducci, M. A., Hseih, W-S., Kim, W. Y., and Simons, J. W. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology, 45: 542-549, 1995.
5. Hoosein, N., Abdul, M., McCabe, R., Gero, E., Deftos, L., Banks, M., Hodges, S., Finn, L., and Logothetis, C. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urol. Oncol., 1: 246-251, 1995.
6. Chen-Kiang, S., Hsu, W., Natkunam, Y., and Zhang, X. Nuclear signaling by interleukin-6. Curr. Opin. Immunol., 5: 124-128, 1993.
7. Kishimoto, T., Akira, S., Narazaki, M., and Taga, T. Interleukin-6 family of cytokines and gp130. Blood, 86: 1243-1254, 1995.
8. Ihle, J. N., and Kerr, I. M. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet., 11: 69-74, 1995.
9. Klein, B., Zhang, X. G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M., and Bataille, R. Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood, 73: 517-526, 1989.
10. Oh, J. W., Katz., A., Harroch, S., Eisenbach, L., Revel, M., and Chebath, J. Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells. Oncogene, 15: 569-577, 1997.
11. Speirs, V., Adams, E. F., Rafferty, B., and White, M. C. Interactive effects of interleukin-6. 17β-estradiol and progesterone on growth and 17β-hydroxysteroid dehydrogenase activity in human breast carcinoma cells. J. Steroid Biochem. Mol. Biol., 46: 11-15, 1993.
12. Takizawa, H., Ohtoshi, T., Ohta, A., Yamashita, N., Hirohata, S., Hirai, K., Hiramatsu, K., and Ito, K. Growth inhibition of human lung cancer cell lines by interleukin-6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res., 53: 4175-4181, 1993.
13. Siegall, C. B., Schwab, G., Nordan, R. P., FitzGerald, D. J., and Pastan, I. Expression of the interleukin-6 receptor and interleukin-6 in prostate carcinoma cells. Cancer Res., 50: 7786-7788, 1990.
14. Siegsmund, M. J., Yamazaki, H., and Pastan, I. Interleukin-6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J. Urol., 151: 1396-1399, 1994.
15. Serve, H., Steinhauser, G., Oberberg, D., Flegel, W. A., Northoff, H., and Berdel, W. E. Studies on the interaction between interleukin-6 and human malignant nonhematopoietic cell lines. Cancer Res., 51: 3862-3866, 1991.
16. Degeorges, A., Tatoud, R., Fauvel-Lafeve, F., Podgorniak, M. P., Millot, G., de Cremoux, P., and Calvo, F. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int. J. Cancer, 68: 207-214, 1996.
17. Okamoto, M., Lee, C., and Oyasu, R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res., 57: 141-146, 1997.
18. Ritchie, C. K., Andrews, L. R., Thomas, K. G., Tindall, D. J., and Fitzpatrick, L. A. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology, 138: 1145-1150, 1997.
19. Okamoto, M., Lee, C., and Oyasu, R. Autocrine effect of androgen on proliferation of an androgen-responsive prostatic carcinoma cell line, LNCaP: role of interleukin-6. Endocrinology, 138: 5071-5074, 1997.
20. Levesque, E., Beaulieu, M., Guillemette, C., Hum, D. W., and Belanger, A. Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyl-transferase expression and activity in the LNCaP cell line. Endocrinology, 139: 2375-2381, 1998.
21. Qiu, Y., Ravi, L., and Kung, H-J. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature (Lond.), 393: 83-85, 1998.
22. Van der Kwast, T. H., Schalken, J., Ruizeveld de Winter, J. A., van Vroonhoven, C. C. J., Mulder, E., Boersma, W., and Trapman, J. Androgen receptors in endocrinetherapy-resistant human prostate cancer. Int. J. Cancer, 48: 189-193, 1991.
23. Hobisch, A., Culig, Z., Radmayr, C., Bartsch, G., Klocker, H., and Hittmair, A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res., 55: 3068-3072, 1995.
24. Hobisch, A., Culig, Z., Radmayr, C., Bartsch, G., Klocker, H., and Hittmair, A. Androgen receptor status of lymph node metastases from prostate cancer. Prostate, 28: 129-135, 1996.
25. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., and Klocker, H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res., 54: 5474-5478, 1994.
26. Nazareth, L. V., and Weigel, N. L. Activation of the human androgen receptor through a protein kinase A signaling pathway. J. Biol. Chem., 271: 19900-19907, 1996.
27. Culig, Z., Hobisch, A., Hittmair, A., Cronauer, M. V., Radmayr, C., Zhang, J., Bartsch, G., and Klocker, H. Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells. Prostate, 32: 106-114, 1997.
28. Speirs, V., Adams, E. F., and White, M. C. The anti-estrogen tamoxifen blocks the stimulatory effects of interleukin-6 on 17β-hydroxysteroid dehydrogenase activity in MCF-7 cells. J. Steroid Biochem. Mol. Biol., 46: 605-611, 1993.
29. Hocke, G. M., Barry, D., and Fey, G. H. Synergistic action of interleukin-6 and glucocorticoids is mediated by the interleukin-6 response element of the rat α2-macroglobulin gene. Mol. Cell. Biol., 12: 2282-2294, 1992.
30. Eder, I. E., Stenzl, A., Hobisch, A., Cronauer, M. V., Bartsch, G., and Klocker, H. Expression of transforming growth factors β-1, β-2 and β-3 in human bladder carcinomas. Br. J. Cancer, 75: 1753-1760, 1997.
31. Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1978.
32. Cronauer, M. V., Klocker, H., Talasz, H., Geisen, F. H., Hobisch, A., Radmayr, C., Böck, G., Culig, Z., Schirmer, M., Reissigl, A., Bartsch, G., and Konwalinka, G. Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. Prostate, 28: 172-181, 1996.
33. Veldscholte, J., Ris-Stalpers, C, Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., and Brinkmann, A. O. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun., 17: 534-540, 1990.
34. Young, C. Y. F., Montgomery, B. T., Andrews, P. E., Qiu, S., Bilhartz, D. L., and Tindall, D. J. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res., 51: 3748-3752, 1991.
35. Montgomery, B. T., Young, C. Y., Bilhartz, D. L., Andrews, P. E., Prescott, J. L., Thompson, N. F., and Tindall, D. J. Hormonal regulation of prostate-specific antigen (PSA) in the human adenocarcinoma cell line, LNCaP. Prostate, 21: 63-73, 1992.
36. Zhao, X. Y., Ly, L. H., Peehl, D. M., and Feldman, D. 1α,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology, 138: 3290-3298, 1997.
37. Bellido, T., Jilka, R. L., Boyce, B. F., Girasole, G., Broxmeyer, H., Dalrymple, S. A., Murray, R., and Manolagas, S. C. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. J. Clin. Invest., 95: 2886-2895, 1995.
38. Lin, S-C., Yamate, T., Taguchi, Y., Borba, V. Z. C., Girasole, G., O'Brien, C. A., Bellido, T., Abe, E., and Manolagas, S. C. Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. J. Clin. Invest., 100: 1980-1990, 1997.
39. Culig, Z., Hobisch, A., Hittmair, A., Cronauer, M. V., Radmayr, C., Bartsch, G., and Klocker, H. Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy. Drugs Aging, 10: 50-58, 1997.
40. Kokontis, J., Takakura, K., Hay, N., and Liao, S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res., 54: 1566-1573, 1994.
41. Newton, C. J., Buric, R., Trapp, T., Brockmeier, S., Pagotto, U., and Stalla, G. K. The unliganded estrogen receptor (ER) transduces growth factor signals. J. Steroid Biochem. Mol. Biol., 48: 481-486, 1994.
42. Gupta, C., Chandorkar, A., and Nguyen, A. P. Activation of androgen receptor in epidermal growth factor modulation of fetal mouse sexual differentiation. Mol. Cell. Endocrinol., 123: 89-95, 1996.
43. Thomson, A. A., Foster, B. A., and Cunha, G. R. Analysis of growth factor and receptor mRNA levels during development of the rat seminal vesicle and prostate. Development (Camb.), 124: 2431-2439, 1997.
44. Nakhla, A. M., Romas, N. A., and Rosner, W. Estradiol activates the prostate androgen receptor and prostate-specific antigen secretion through the intermediacy of sex hormone-binding globulin. J. Biol. Chem., 272: 6838-6841, 1997.
45. MacDonald, A., and Habib, F. K. Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br. J. Cancer, 65: 177-182, 1992.
46. Nakhla, A. M., and Rosner, W. Stimulation of prostate cancer growth by androgens and estrogens through the intermediacy of SHBG. Endocrinology, 137: 4126-4129, 1996.
47. Douglas, A. M., Goss, G. A., Sutherland, R. L., Hilton, D. J, Berndt, M. C., Nicola, N. A., and Begley, C. G. Expression and function of members of the cytokine receptor superfamily on breast cancer cells. Oncogene, 14: 661-669, 1997.
48. Nishimura, R., Moriyama K., Yasukawa, K., Mundy, G. R., and Yoneda, T. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells. J. Bone Miner. Res., 13: 777-785, 1998.
49. Ikonen, T., Palvimo, J. J., Kallio, P. J., Reinikainen, P., and Jänne, O. A. Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation. Endocrinology, 135: 1359-1366, 1994.
50. Sartorius, C. A., Tung, T., Takimoto, G. S., and Horwitz, K. B. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J. Biol. Chem., 268: 9262-9266, 1993.
51. Nordeen, S. K., Bona, B. J., and Moyer, M. L. Latent agonistic activity of the steroid antagonist, RU 486, is unmasked in cells treated with activators of protein kinase A. Mol. Endocrinol., 7: 731-742, 1993.